Skip to main content

Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.

Publication ,  Journal Article
Hong, H; Friedland, A; Hu, M; Anstrom, KJ; Halabi, S; McKinnon, JE; Amaravadi, R; Rojas-Serrano, J; Abella, BS; Portillo-Vázquez, AM; Woods, CW ...
Published in: BMJ Open
June 16, 2023

OBJECTIVE: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs). DATA SOURCES: PubMed and EMBASE databases were searched to identify randomised trials studying HCQ. STUDY SELECTION: Ten RCTs were identified (n=5079 participants). DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used in this systematic review and meta-analysis between HCQ and placebo using a Bayesian random-effects model. A pre-hoc statistical analysis plan was written. MAIN OUTCOMES: The primary efficacy outcome was PCR-confirmed SARS-CoV-2 infection and the primary safety outcome was incidence of adverse events. The secondary outcome included clinically suspected SARS-CoV-2 infection. RESULTS: Compared with placebo, HCWs randomised to HCQ had no significant difference in PCR-confirmed SARS-CoV-2 infection (OR 0.92, 95% credible interval (CI): 0.58, 1.37) or clinically suspected SARS-CoV-2 infection (OR 0.78, 95% CI: 0.57, 1.10), but significant difference in adverse events (OR 1.35, 95% CI: 1.03, 1.73). CONCLUSIONS AND RELEVANCE: Our meta-analysis of 10 RCTs investigating the safety and efficacy of HCQ as pre-exposure prophylaxis in HCWs found that compared with placebo, HCQ does not significantly reduce the risk of confirmed or clinically suspected SARS-CoV-2 infection, while HCQ significantly increases adverse events. PROSPERO REGISTRATION NUMBER: CRD42021285093.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

June 16, 2023

Volume

13

Issue

6

Start / End Page

e065305

Location

England

Related Subject Headings

  • SARS-CoV-2
  • Pre-Exposure Prophylaxis
  • Hydroxychloroquine
  • Humans
  • Health Personnel
  • COVID-19 Drug Treatment
  • COVID-19
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hong, H., Friedland, A., Hu, M., Anstrom, K. J., Halabi, S., McKinnon, J. E., … Rajasingham, R. (2023). Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open, 13(6), e065305. https://doi.org/10.1136/bmjopen-2022-065305
Hong, Hwanhee, Anne Friedland, Mengyi Hu, Kevin J. Anstrom, Susan Halabi, John E. McKinnon, Ravi Amaravadi, et al. “Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.BMJ Open 13, no. 6 (June 16, 2023): e065305. https://doi.org/10.1136/bmjopen-2022-065305.
Hong H, Friedland A, Hu M, Anstrom KJ, Halabi S, McKinnon JE, et al. Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open. 2023 Jun 16;13(6):e065305.
Hong, Hwanhee, et al. “Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.BMJ Open, vol. 13, no. 6, June 2023, p. e065305. Pubmed, doi:10.1136/bmjopen-2022-065305.
Hong H, Friedland A, Hu M, Anstrom KJ, Halabi S, McKinnon JE, Amaravadi R, Rojas-Serrano J, Abella BS, Portillo-Vázquez AM, Woods CW, Hernandez AF, Boulware DR, Naggie S, Rajasingham R. Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open. 2023 Jun 16;13(6):e065305.

Published In

BMJ Open

DOI

EISSN

2044-6055

Publication Date

June 16, 2023

Volume

13

Issue

6

Start / End Page

e065305

Location

England

Related Subject Headings

  • SARS-CoV-2
  • Pre-Exposure Prophylaxis
  • Hydroxychloroquine
  • Humans
  • Health Personnel
  • COVID-19 Drug Treatment
  • COVID-19
  • 52 Psychology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences